Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay

International Journal of Biological Markers

Volumn 18, Issue 1, 2003, Pages 13-20

  Muller V ^a   Thomssen, Christoph ^a   Karakas, C ^a   Eustermann, I ^a   Porras, J Ramirez ^a   Coith, C ^a   Berger, J ^a   Loning T ^a   Janicke F ^a   Pantel, K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Breast cancer; ELISA; HER 2 neu; Immunohistochemistry; In situ hybridization

Indexed keywords

BUFFER; MONOCLONAL ANTIBODY; ONCOPROTEIN; ONCOPROTEIN MONOCLONAL ANTIBODY TAB 250; PROTEIN P185; TYLOXAPOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST; BREAST CANCER; BREAST SURGERY; CONTROLLED STUDY; CORRELATION FUNCTION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACT; FEMALE; GENE AMPLIFICATION; HEALTH CARE COST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; RANK SUM TEST; STAINING; TISSUE LEVEL; TISSUE SECTION;

EID: 0142217971     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/jbm.2008.501     Document Type: Article

References (42)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
3. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989; 7: 1120-8.
4. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18: 3651-4.
5. Harris LN, Liotcheva V, Broadwater G, et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 2001; 19: 1698-706.
6. Harbeck N, Ross JS, Yurdseven S, et al. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer. Int J Oncol. 1999; 14: 663-71.
7. Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990; 50: 4332-7.
8. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10: 1049-56.
9. Paik S, Bryant J, Park C, et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90: 1361-70.
10. Petit T, Borel C, Ghnassia JP, et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res 2001; 7: 1577-81.
11. Konecny G, Thomssen C, Pegram M, et al. HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. Proc ASCO 2001; Abstr 88.
12. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808-16.
13. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19: 2334-56.
14. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999; 26: 78-83.
15. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16: 413-28.
16. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
17. Kallioniemi OP, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 1992; 89: 5321-35.
18. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996; 13: 63-72.
19. Persons DL, Borelli KA, Hsu PH. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol 1997; 10: 720-7.
20. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000; 157: 1467-72.
21. Friedrichs K, Lohmann D, Hofler H. Detection of HER-2 oncogene amplification in breast cancer by differential polymerase chain reaction from single cryosections. Virchows Arch B Cell Pathol Incl Mol Pathol 1993; 64: 209-12.
22. De Cremoux P, Martin EC, Vincent-Salomon A, et al. Quantitative PCR analysis of c-erb B-2 (HER2/neu) gene amplification and comparison with p185(HER2/neu) protein expression in breast cancer drill biopsies. Int J Cancer 1999; 83: 157-61.
23. Singleton, TP, Niehans GA, Gu, F, et al. Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol 1992; 23: 1141-50.
24. Kerns BJ, Jordan PA, Huper G, Marks JR, Iglehart JD, Layfield LJ. Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer. Mod Pathol 1993; 6: 673-8.
25. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994; 54: 2771-7.
26. Penault-Llorca F, Adelaide J, Houvenaeghel G, Hassoun J, Birnbaum D, Jacquemier J. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation. J Pathol 1994; 173: 65-75.
27. Harbeck N, Alt U, Berger U, et al. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 2001; 7: 2757-64.
28. Janicke F, Prechtl A, Thomssen C, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-20.
29. Look MP, Van Putten WL, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-28.
30. Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 2000; 27 (suppl 11): 46-52.
31. Valeron PF, Chirino R, Fernandez L, et al. Validation of a differential PCR and an ELISA procedure in studying HER-2/neu status in breast cancer. Int J Cancer 1996; 65: 129-33.
32. Dittadi R, Catozzi L, Gion M, et al. Comparison between Western blotting, immunohistochemical and ELISA assay for p185neu quantitation in breast cancer specimens. Anticancer Res 1993; 13: 1821-40.
33. Dittadi R, Brazzale A, Pappagallo G, et al. ErbB2 assay in breast cancer: Possibly improved clinical information using a quantitative method. Anticancer Res 1997; 17: 1245-7.
34. Sweep CG, Geurts-Moespot J, Grebenschikov N, et al. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 1998; 78: 1434-141.
35. Di Leo A, Larsimont D, Gancberg D, et al. HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 2001; 12: 1081-109.
36. Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002; 20: 1000-7.
37. Kumamoto H, Sasano H, Taniguchi T, Suzuki T, Moriya T, Ichinohasama R. Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: Application in screening of patients for trastuzumab (Herceptin) therapy. Pathol Int 2001; 51: 579-84.
38. Reese DM, Small EJ, Magrane G, Waldman FM, Chew K, Sudilovsky D, HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol 2001; 116: 234-9.
39. Bartlett JM, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 2001; 195: 422-48.
40. Thomson TA, Hayes MM, Spinelli JJ, et al. HER-2/neu in breast cancer: Interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 2001; 14: 1079-86.
41. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 14: 2587-295.
42. Konecny G, Untch M, Arboleda J, et al. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin Cancer Res 2001; 7: 2448-57.